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Abstract
The μ-opioid receptor (MOR) is the primary target for opioid analgesics. MOR induces analgesia 
through the inhibition of second messenger pathways and the modulation of ion channels activity. 
Nevertheless, cellular excitation has also been demonstrated, and proposed to mediate reduction of 
therapeutic efficacy and opioid-induced hyperalgesia upon prolonged exposure to opioids. In this 
mini-perspective, we review the recently identified, functional MOR isoform subclass, which 
consists of six transmembrane helices (6TM) and may play an important role in MOR signaling. 
There is evidence that 6TM MOR signals through very different cellular pathways and may 
mediate excitatory cellular effects rather than the classic inhibitory effects produced by the 
stimulation of the major (7TM) isoform. Therefore, the development of 6TM and 7TM MOR 
selective compounds represent a new and exciting opportunity to better understand the 
mechanisms of action and the pharmacodynamic properties of a new class of opioids.
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1. Introduction: biphasic cellular inhibitory and excitatory effects of MOR 
agonists
Opioids are the most frequently used and effective analgesics for the treatment of moderate 
to severe pain. Unfortunately, both acute and chronic use is frequently associated with a 
number of adverse side effects such as respiratory depression, nausea, constipation, itching, 
xerostomia, drowsiness, as well as physical and psychological addiction. In addition, the 
prolonged use of opioids may lead to reduced efficacy (tolerance) and a clinically 
significant problem of post dosing opioid-induced hyperalgesia (OIH).1-3 At a cellular level, 
MOR is a primary target for clinically used opioids, and MOR-induced analgesia is due to 
the initiation of presynaptic and/or postsynaptic inhibitory processes that decrease the 
electrical excitability, neurotransmitter release, and/or pro-nociceptive processes.
The canonical seven transmembrane (7TM) MOR is a member of the G-protein-coupled 
receptor (GPCR) family. MOR signaling involves activation of a pertussis toxin (PTX)-
sensitive G-proteins (Gαi/o). Receptor activation leads to the dissociation of the 
heterotrimeric G-protein complex: the release of the α subunit inhibits adenylyl cyclase, 
while the βγ subunit activates K+ channels or inhibits voltage-gated Ca2+ channels 
(VGCC).4-6 MOR-mediated inhibition of VGCC on the central presynaptic terminals of 
primary afferent nociceptors is thought to be one of the primary mechanisms mediating the 
spinal analgesic effects of opiates. K+ channel activation is a primary mechanism underlying 
the inhibitory actions of MOR on central nervous system neurons.7-9
Similarly to the analgesic effects of opioids, tolerance and OIH are also manifested in both 
animals and human following acute or chronic dosing.10-13 The neural mechanisms that 
underlie hyperalgesic effects are poorly understood, but are dependent on the concentration 
of the drug and the duration of exposure.4,14 A biphasic effect of opioids on cAMP 
formation and substance P release has also been demonstrated.4,14-18 There is evidence that 
the excitatory actions of MOR reflect a switch in the G protein coupling profile of the MOR 
from G1 to both Gs 4,19-21 and Gq,14 as well as adenylyl cyclase (AC) activation by 
Gβγ. 18,21 There is additional evidence for a critical role of β-arrestin in MOR desensitization 
and tolerance. It has been shown that in mice lacking β-arrestin-2, MOR desensitization does 
not occur after chronic morphine treatment and these animals fail to develop tolerance, 
although they still develop physical dependence.22
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2. Genomic organization of OPRM1 gene
The major isoform of MOR, also called MOR-1, is coded by exons 1, 2, 3 and 4 of MOR 
gene locus (OPRM1), where exon 1 codes for the first transmembrane domain and exons 2 
and 3 code for all the other transmembrane domains. Gene structure is highly conserved 
between human, mouse and rat. Today, at least 30 splice variants of MOR in mice, 16 in 
rats and 19 in humans have been identified.23 There are two common splicing patterns of 
OPRM1 that involve the C-terminus and N-terminus. C-terminus variants contain exons 1, 2 
and 3 and code for all seven transmembrane domains, but differ structurally and functionally 
at the intracellular domains. The N-terminus also has a number of variants, some of which 
encode for truncated receptors with only six transmembrane domains (6TM, coded by exons 
2 and 3). While other truncated receptors have been reported,24-27 analysis of the functional 
significance of truncated MOR receptors is still ongoing. Some truncated receptors can 
modulate the activity of the full version of receptor24-26 or change the biological activity of 
the protein, sometimes in the opposite direction.27
The 6TM MOR variants were first cloned from mouse.28 Five 6TM alternatively spliced 
isoforms were first reported, of which three (MOR-1G, MOR-1M, and MOR-1N) have an 
initial methionine positioned at exon 11 that codes for the N-terminus of the protein, and 
two isoforms (MOR-1K and MOR-1L) have the initial methionine positioned at the 
beginning of exon 2. The latter MOR mRNA splice variants also code for a short upstream 
peptide. The potential for these mRNA splice variants to code for 6TM MOR isoform has 
not been explored. Furthermore, none of the five variants have been shown to bind opioid 
ligands by [3H]-DAMGO displacement experiments, and thus, the functionality of these 
receptor variants has been questioned.28
The first described human 6TM OPRM1 isoform29 was referred to as MOR-3. It has no 
reported analogue in mouse or rat, and its first methionine is positioned at the beginning of 
exon 2. On a functional level, COS-1 cells transiently overexpressing MOR-3 receptor 
exhibit a dose-dependent release of nitric oxide (NO) following treatment with morphine. 
MOR-3 possesses a unique intracellular C-terminal amino acid sequence that has been 
hypothesized to serve as a coupling or docking domain required for constitutively expressed 
NO synthase activation.30 The expression of MOR-3 has been detected in human vascular 
tissue, mononuclear cells, polymorphonuclear cells, and human neuroblastoma cells by 
northern blot and reverse transcription polymerase chain reaction (RT-PCR).29 The 
physiological and cellular pathways whereby this isoform contributes to opioid responses 
have not been yet identified.
Using comparative genomic approaches we reported that the human OPRM1 gene is much 
more complex than previously shown and has orthologs to all described mouse exons.31 
Our association study analysis identified a new potentially functional single nucleotide 
polymorphism (SNP), namely rs563649, which showed strong contribution to variability in 
pain sensitivity and morphine analgesia. This finding allowed us to clone a new human 
isoform (MOR-1K) that carries SNP rs563649. The human MOR-1K is orthologous to 
mouse MOR-1K, containing an ortholog of mouse exon 13. Although similar to the human 
MOR-3 variant reported by Cadet29 and initiated from methionine in exon 2, MOR-1K 
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codes for a truncated 6TM receptor isoform with an intracellular domain identical to the 
major MOR-1 isoform, which is different from MOR-3. In contrast to MOR-3, MOR-1K is 
also expressed in neuronal cell lines, neuronal tissues, and brain regions that mediate the 
pharmacodynamic effects of MOR agonists. The minor T allele situated in the 5’-
untranslated region (5’-UTR) of MOR-1K mRNA is associated with higher pain sensitivity 
as well as a poorer analgesic response to morphine. It codes for higher translation efficiency 
of the 6TM receptor isoform,31 suggesting that the expression of the 6TM variant produces a 
pronociceptive effect.
In line with these observations, cellular studies with MOR-1K suggest that, after agonist 
activation, this isoform drives excitatory rather than the classic inhibitory cellular responses 
following the stimulation of the 7TM isoform.32 Indeed, morphine-induced activation of 
MOR-1K increases the production of excitatory mediators (e.g., Ca2+ and NO). 
Furthermore, immunoprecipitation experiments reveal that MOR-1K couples to Gαs, 
rather than Gαi/o (which classically couples with the major MOR1 isoform).32 These data 
suggest that MOR-1K can function as a counterbalance to the actions mediated by the 7TM 
isoform and may mediate the molecular processes that underlie OIH and pharmacological 
tolerance.
The human ortholog of mouse exon 11 also has been cloned by Pan and coworkers.33 Four 
new alternatively spliced forms (MOR-1G1, MOR-1G2, MOR-1I and MOR-1H) have been 
identified that contain exon 11 spliced either directly to exon 2 or to exon 1 through a 
variable 3’ acceptor splice site.33 These RNAs code for either the extended 7TM receptor 
isoforms (MOR-1I and MOR-1H) or for 6TM receptor isoforms, namely MOR-1G1 and 
MOR-1G2. While MOR-1G1 codes for the same amino acid sequence of the MOR-1K 
variant, MOR-1G2 is characterized by the presence of additional 10 residues at the N-
terminal domain of the protein. Importantly, the human exon 11, which was cloned by Pan 
and coworkers, corresponds to the predicted exon 11 by Shabalina et al. revealed by 
comparative genomic approaches.31 This observation suggest the existence of additional 
exons, and reconfirms the existence of a unique class of human 6TM receptor isoforms 
(Figure 1).
3. Receptor structure for 7TM and 6TM MOR
Before the MOR structure was resolved at high-resolution,34 in silico modeling was 
performed to predict its structure.35-38 Using homology modeling,38,39 we have 
reconstructed and further refined a structural model for 7TM MOR (Figure 2A).40 Based on 
the computational prediction of 7TM MOR, we designed several 7TM MORs carrying 
mutations in the ligand binding pocket, as well as 7TM MOR variants with mutations 
outside of the binding site as controls.38 Results of competitive radioligand displacement 
experiments and cAMP inhibition assay of the proposed mutants were fully consistent with 
our structural model. The model is also consistent with the recently solved MOR crystal 
structure,34 with a deviation of ~3.5Å.
Compared to 7TM MOR, the 6TM isoform lacks a segment of 100 residues in the N-
terminal, including the extra-cellular domain as well as the first transmembrane helix 
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(TMH1) (Figure 2B). The absence of TMH1 in 6TM MOR paves the way to a plethora of 
different structural hypotheses that could be potentially related to the excitatory cellular 
response observed upon stimulation of 6TM isoform. The newly membrane exposed surface 
of 6TM MOR is characterized by a different charge distribution (Figure 2C). Therefore, a 
possible rearrangement in the plasma membrane of the remaining helices may result in 
differences in ligand binding and G protein activation compared to wild type isoform. The 
lack of TMH1 in 6TM MOR can also alter the functional plasticity of the receptor and its 
ability to interact with specific intracellular signaling proteins (i.e., G protein and/or β-
arrestin isoforms). Furthermore, it cannot be excluded that 6TM competes with 7TM MOR 
for the binding of opioids or for interactions with other GPCRs, thus reshaping intracellular 
GPCR-dependent signaling cascades and the resulting cellular responses.41 All of these 
scenarios are equally likely at this time. Therefore, there is a substantial need to further 
structural and functional investigations of the biological signaling mechanism mediated by 
6TM MOR.
4. Cellular localization of 7TM and 6TM MOR isoforms
The cellular localization of the two MOR isoforms has recently been reported for both 
human and mouse.32,42 Two independent groups have showed that the 6TM MOR isoform 
overexpressed in mammalian cells is not constitutively expressed on the cytoplasmic 
membrane, but instead it is localized in intracellular compartments (Figure 3). Nevertheless, 
it has been shown that cells overexpressing intracellular 6TM bind fluorescently labeled 
naloxone.32 Furthermore, the co-transfection of the orphanin FQ receptor ORL1 (opioid 
receptor-like) with the 6TM variant enables high-affinity binding of the recently 
synthesized 6TM MOR ligand iodobenzoylnaltrexamide (IBNtxA) to 6TM MOR.42 No 
IBNtxA binding is observed in cells transfected with either 6TM MOR or ORL1 alone, 
however, binding is detected in brain tissues from 7TM MOR knockout (KO) mice.42
Taken together, these results suggest that the lack of the first transmembrane in MOR 
protein structure dramatically alters the subcellular localization of 6TM MOR and implies 
that the expression of the 6TM variant alone is insufficient to enable ligand binding. It is 
still possible that similarly to the sigma receptor (Sigma-1)43 or estrogen receptor GPR30,44 
intracellularly localized 6TM can bind ligands and produce cellular signaling. It should also 
be recognized that 6TM MOR may be translocated to the cell surface with the aid of a 
cytoplasmic chaperone. Alternatively, the presence of a plasma membrane GPCR partner 
such as ORL1 or other GPCRs can coordinate plasma membrane co-localization and 
assembly, thus leading to function as a mosaic of proteins that act in concert to mediate the 
cellular signaling evoked by opioid ligands.
5. Behavioral studies in knockout mice demonstrate functional differences 
in MOR isoforms
Several studies have shown that OPRM1 is essential for morphine's analgesic actions 
because complete OPRM1 KO mice show a complete loss of morphine analgesia.45-47 
However, KO mice with the deletion of only exon 1 or only exon 11 show substantial 
differences in their sensitivity to opioids. Exon 1 KO mice, which should still express 6TM 
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receptor variants, show reduced analgesic response to heroin and morphine 6-glucuronide 
(M6G), but do not respond to methadone or morphine.48 In contrast, mice lacking exon 11, 
which can still produce 7TM receptor variants, do not show an analgesic response to heroin, 
fentanyl, and M6G, but are responsive to methadone and morphine.49 The absence of 
analgesic response to morphine in exon 1 KO mice, but not in exon 11 KO mice, is in line 
with the proposed hypothesis that 7TM but not 6TM MOR isoform, exclusively or largely, 
underlies cellular inhibitory effects of morphine and contributes to analgesia. More 
importantly, our results pertaining to the 6TM-dependent excitatory cellular effects of 
morphine32 also suggest that exon 1 KO mice may show reduced or hyperalgesic responses 
to morphine administration, while exon 11 KO mice, which lack the excitatory 6TM 
receptor variant, should show diminished OIH. This model has been indirectly examined in 
“triple KO” mice that lack the first exons in all three genes encoding for opioid receptors (μ, 
δ, and κ). The thermal nociceptive responses to morphine and oxymorphone in triple KO 
compared to control mice have been examined. The acute administration of test opioids 
(morphine or oxymorphone) in control animals evokes a profound analgesia that is absent in 
the triple KO mice. In contrast, a continuous infusion of either morphine or oxymorphone 
evokes hyperalgesia in the triple KO mice in comparison with control mice.50 Since the 
original MOR KO line was derived from an exon 1 KO variant,48 which leaves exon 11 
available to code for 6TM variants of MOR, triple KO mice should completely lack 7TM 
but not 6TM variants of MOR.
Recently, Majumdar et al.42,51 demonstrated a potent opioid analgesia evoked in triple KO 
mice by IBNtxA and iodobenzoylnaloxamide (IBNalA), which are both morphinane 
derivatives. The analgesia evoked by these compounds was associated with a lack of 
respiratory depression, physical dependence, reward behavior, and significant constipation. 
Analgesia was lost in the exon 11 MOR-1 KO mice indicating that IBNtxA and IBNalA 
effects involve exon 11-associated MOR-1 variants, those coding for the 6TM MOR 
isoform. The authors reported that IBNtxA and IBNalA bind to brain lysates of the triple 
KO mice, which suggests the direct interaction with 6TM MOR isoform.42 However, they 
also demonstrated that these opioids showed high affinity for the reference 7TM variants of 
the three opioid receptor subtypes (in vitro affinity data and competitions studies performed 
with radiolabelled IBNTxA and IBNalA are reported in Tables 1 and 2, respectively).52
6. A paradox
An apparent paradox to the hypothesis that agonists of the 6TM isoform may produce 
excitatory effects, OIH, and analgesic tolerance to opioids needs to be acknowledged. First, 
opioid analgesia is evoked by heroin, fentanyl, and M6G in exon 1 KO (6TM sparing) mice 
and greatly diminished in exon 11 KO (7TM sparing).49 Furthermore, in studies by 
Majumdar and co-workers, IBNtxA and IBNalA produced analgesia in triple exon 1 KO 
mice.42,51 These results are not in line with the observed hyperalgesic effects of the minor T 
allele of rs563649, coding for higher expression of 6TM MOR-1K variant,31 and the 6TM-
dependent cellular excitatory effects of morphine and IBNtxA.32,53 However, there are 
several possible reasons for this apparent paradox. First, it is possible that there are still 
undiscovered OPRM1 spliced forms that contain exon 11 but not exon 1, that code for a 
functional 7TM isoform, or there is a difference in a signaling between 6TM MOR isoforms 
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initiated from exon 11 and exon 2 and varying in their N-terminus (such as MOR-1G2 and 
MOR-1K23,54). A second possible explanation is that both 7TM and 6TM receptor isoforms 
are promiscuous in terms of G-protein binding capacity and both isoforms can bind either Gi 
or Gs proteins,55 though, as a general rule, the stimulation of the 7TM isoform signals 
through binding with Gi and stimulation of the 6TM isoform favors Gs binding. Certain 
“biased” agonists may produce sufficient thermodynamic changes to permit “protean 
agonism” whereby an agonist is able to produce a receptor activation state and signaling 
through a non-canonical pathway.56 In line with this hypothesis, potentially, developmental 
adaptation in the exon 1 KO animals may take place that would switch the balance of 
Gi/Gs/Gq coupling for 6TM variants in the absence of expression of 7TM variants. 
Furthermore, it can be hypothesized that specific GPCRs can partner with 6TM MOR at the 
cellular membrane (see section entitled cellular localization of 7TM and 6TM MOR 
isoforms) producing a temporally dynamic mosaic of molecular partners and, thus, different 
cellular signaling responses. The macromolecular composition may be influenced by the 
individual's history of opioid exposure or exposures to physical and psychological stressors 
that influence the expression and cellular distribution of 6TM MOR resulting in 
qualitative and quantitative differences in the pharmacodynamic responses to opioids. These 
responses can also depend on the concentration of a ligand, such that a low concentration 
may produce analgesia and higher concentrations may produce hyperalgesia. In line with 
this suggestion, the concentrations of morphine and IBNtxA that produced cellular 
excitatory effects occur at relatively high concentration (1-10 μM).32,53 Finally, it should be 
noted that the M6G analgesia reported in exon 1 MOR1 KO mice (6TM sparing) has not 
been uniformly observed. A recent study by van Dorp and coworkers57 showed both acute 
and chronic M6G administration to triple KO mice (deletion of exon 1 of MOR1, 6TM 
sparing) leads to a profound hyperalgesia.
7. Conclusions and significance
MOR agonists are the most widely used analgesics, prescribed for both acute postoperative 
pain and chronic pain conditions; yet, there are substantial side effects that limit usage. 
Thus, a further understanding of the molecular and cellular mechanisms that contribute to 
the analgesic, hyperalgesic, and analgesic tolerance effects of opioids is needed. Current 
published findings provide evidence that the 6TM MOR isoform is not just another 
alternatively spliced form of OPRM1, but instead it displays substantial differences in 
cellular distribution, evoked cellular responses, contributions to the cellular excitatory 
responses to opioids, and it shows evidence of both hyperalgesic and analgesic responses. 
Because of the potentially dual contribution of the 6TM MOR isoform to analgesic 
signaling, further research targeting this isoform is warranted. The development of highly 
selective and specific agonists and antagonists of the 6TM and 7TM MOR isoforms, as well 
as ligand biased compounds are required to elucidate the biological and cellular 
properties engaged by these distinct isoforms subclasses. The elucidation of signaling 
pathways associated with 6TM and 7TM MOR isoforms, along with understanding of the 
endogenous properties of these isoforms and the ligands that modify the biological activities 
of these MOR variants, will enable the development of opioids that show a high degree of 
analgesic efficacy with fewer side-effects.
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ABBREVIATIONS
MOR μ-opioid receptor
6TM MOR six transmembrane helices μ-opioid receptor
7TM MOR seven transmembrane helices μ-opioid receptor
OIH opioid induced hyperalgesia
VGCC voltage-gated Ca2+ channels
cAMP cyclic adenosine monophosphate
AC adenylyl cyclase
OPRM1 μ-opioid receptor locus
DAMGO Ala-2-MePhe-4-Glyol-5-Enkephalin
COS-1 CV-1 carrying the SV40 genetic material fibroblast-like cells
NO nitric oxide
RT-PCR reverse transcription polymerase chain reaction
SNP single nuclotide polymorphism
MOR-1K μ-opioid receptor carrying the SNP rs563649
TMH1 transmembrane helix 1
GPCR G protein-coupled receptor




HEK-293 human embryonic kidney 293 cells
MYC-tag N-EQKLISEEDL-C
Anti-MYC-FITC fluorescein isothiocyanate-conjugated anti-MYC antibody
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• 6TM MOR is a functional isoform of μ-opioid receptor;
• 6TM MOR has a different cellular localization with respect to 7TM-MOR;
• 6TM MOR may signal via different cellular pathways with respect to 7TM 
MOR;
• 6TM MOR stimulation may mediate excitatory cellular effects.
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Figure 1. Schematic structure of human OPRM1 spliced variants
(A) All predicted and cloned exons of human OPRM1 gene are in accordance with the NCBI 
database, UCSC genome browser GRCh37/hg19. Exons and introns are shown by vertical 
and horizontal boxes, respectively. Solid boxes represent constitutive exons coding for 
transmembrane dolmens 2-7. (B) All cloned alternatively spliced variants of OPRM1 coding 
for 7TM receptor isoforms. (C) All cloned alternatively spliced variants of OPRM1 coding 
for 6TM receptor isoforms, (p) partial sequence, (*) exons with variable exon/intron 
boundaries. Start codons of MOR isoforms are schematically indicated by lower vertical 
bars, while stop codons are indicated by upper vertical bars. Maximal sizes of human exons 
(for lower panel) are shown in parentheses (nt): exon 11 (206), exon 1 (580), exon T (117), 
exon 14 (105), exon 13 (1200), exon 2 (353), exon 3 (521), exon Y (109), exon 16 (314), 
exon X (1271), exon 17 (128), exon 5 (1013), exon 4 (304), exon 18 (412), exon 6 (124), 
exon 7 (89), exon 9 (393).
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Computer model of 7TM and 6TM MOR. (A) The experimentally validated structure model 
of 7TM MOR. The protein is shown in cartoon representation with rainbow color for N-
(blue) to C-terminal (red). The extra-cellular loop is white with a weak propensity to form β-
strands. (B) The initial 6TM model with the N-terminal 100 residues excised from the 7TM 
model. (C) The surface of 6TM model structure colored according to the local electrostatic 
potential. Blue and red colors correspond to positively and negatively charged surfaces, 
respectively, and white color corresponds the neutral hydrophobic ones.
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Cellular localization of 7TM or 6TM MOR isoforms shows. Confocal images of HEK-293 
cells expressing 7TM or 6TM MOR: A) 7TM MOR localizes on the cell surface, B) 6TM 
isoform is mainly localized in intracellular compartments. HEK-293 cells were transiently 
transfected with plasmids encoding MYC-tagged 7TM or FLAG-tagged 6TM. After forty-
eight hours cells were fixed and stained with either Anti-MYC-FITC Antibody or Anti-
DYKDDDDK Tag Antibody (Alexa Fluor 488 conjugate); DNA was counterstained with 
Hoechst 33342. Scale bar: 10 μm.
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Table 1





IBNTxA 2.50 ± 0.82 0.58 ± 0.16 0.23 ± 0.16




IBNTxA 0.11 ± 0.02 0.24 ± 0.005 0.027 ± 0.0001
IBNalA 0.22 ± 0.03 2.5 ± 0.22 0.05 ± 0.22
Table adapted from ref. 52.
a
Competition studies of 125I -radiolabelled compounds against 3H-opioids performed with 3H-DAMGO (μ-OR), 3H-DPDPE (δ-OR), and 3H-
U69,593 (κ-OR) at 1 nM concentration in stably transfected CHO Cell lines. Ki values are reported as mean ± SEM; for further details refer to ref 
52.
b
Saturation studies of 125I-labelled compounds in stably transfected CHO cell lines. Kd values are reported as mean ± SEM; for further details 
refer to ref. 52. Abbreviation: DAMGO, D-Ala-N-MePhe-Glyol-enkephalin; DPDPE, D-Penicillamine-2-D-Penicillamine-5-enkephalin; U69,593, 
N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]-acetamide.
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Table 2





CTAP 2.33 ± 0.48 2.96 ± 1.07
Naloxone 4.23 ± 0.42 2.27 ± 0.60
Levallorphan 1.29 ± 0.14 1.69 ± 0.60
Naltrexone 1.15 ± 0.10 2.71 ± 1.0
DAMGO 3.34 ± 0.43 0.45 ± 0.12
Morphine 4.60 ± 1.81 2.52 ± 0.28
δ-OR
DPDPE 1.39 ± 0.67 1.77 ± 0.80
Naltrindole 0.46 ± 0.32 0.50 ± 0.20
κ-OR
norBNI 0.23 ± 0.03 0.19 ± 0.08
5’GNTI 0.15 ± 0.07 0.19 ± 0.05
(−)U50,488H 0.73 ± 0.32 0.95 ± 0.37
Table adapted from ref. 52. Competition studies were performed for each compound against 125IBNTxA and 125IBNalA at 0.1 nM concentration 
in membranes from stably transected CHO cell lines. Ki values are expressed as mean ± SEM; for further information refer to ref. 52. 
Abbreviation: CTAP, D-Phe-Cys-D-Trp-Arg-Thr-Penicillamine-Thr-NH2; DAMGO, D-Ala-N-MePhe-Glyol-enkephalin; DPDPE, D-
Penicillamine-2-D-Penicillamine-5-enkephalin; norBNI, nor-binailorphimine; 5'GNTI, 5'-Guanidinonaltrindole; U50,488U, 2-(3,4-
dichlorophenyl)-N-methyl-N- [(1R,2R)-2-pyrrolidin-1-yl-cyclohexyl]-acetamide.
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